Pharmacokinetics of pregabalin controlled-release in healthy volunteers: Effect of food in five single-dose, randomized, clinical pharmacology studies

Clinical Drug Investigation

Volumn 34, Issue 9, 2014, Pages 617-626

  Chew, Marci L ^a   Plotka, Anna ^a   Alvey, Christine W ^a   Pitman, Verne W ^a   Alebic Kolbah, Tanja ^a   Scavone, Joseph M ^a   Bockbrader, Howard N ^b  

^a PFIZER INC   (United States)

^b BEP Analyses   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREGABALIN; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DELAYED RELEASE FORMULATION; FAT INTAKE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BALANCE DISORDER; BIOEQUIVALENCE; CALORIC INTAKE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FAT CONTENT; FATIGUE; FEMALE; FOOD INTAKE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TIME MANAGEMENT; YOUNG ADULT; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; FAT INTAKE; FOOD DRUG INTERACTION; PHYSIOLOGY; THERAPEUTIC EQUIVALENCE; TIME;

ADULT; ANALGESICS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIETARY FATS; ENERGY INTAKE; FEMALE; FOOD-DRUG INTERACTIONS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; TIME FACTORS; YOUNG ADULT;

EID: 84906938954     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0211-4     Document Type: Article

References (15)

1. Lyrica (pregabalin) [package insert]. Pfizer Inc, New York. 2013. http://labeling.pfizer.com/ShowLabeling.aspx?id=561. Accessed 11 Jun 2014.
2. Lyrica EU product information. Pfizer Limited, Sandwich. 2009. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/000546/WC500046602.pdf. Accessed 11 Jun 2014.
3. Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50:941-50.
4. Corrigan BW, Pool WF, Posvar EL, et al. Metabolic disposition of pregabalin in healthy volunteers [abstract PI-68]. Clin Pharmacol Ther. 2001;69:P18.
5. Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-34.
6. Bockbrader HN, Burger P, Knapp L, Corrigan BW. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia. 2011;52:248-57.
7. Alebic-Kolbah T. Pregabalin: development and validation of an LC-MS/MS method for pediatric studies [abstract TP542]. J Am Soc Mass Spectrom. 2012;23:109.
8. Kellow JE, Borody TJ, Phillips SF, et al. Human interdigestive motility: variations in patterns from esophagus to colon. Gastroenterology. 1986;91:386-95.
9. Kumar D, Wingate D, Ruckebusch Y. Circadian variation in the propagation velocity of the migrating motor complex. Gastroenterology. 1986;91:926-30.
10. Wilson P, Perdikis G, Hinder RA, et al. Prolonged ambulatory antroduodenal manometry in humans. Am J Gastroenterol. 1994;89:1489-95.
11. Soffer EE, Thongsawat S, Ellerbroek S. Prolonged ambulatory duodeno-jejunal manometry in humans: normal values and gender effect. Am J Gastroenterol. 1998;93:1318-23.
12. Freynhagen R, Serpell M, Emir B, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract. 2013. doi:10.1111/papr.12146.
13. Chew ML, Alvey CW, Plotka A, et al. Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig. 2014. doi:10.1007/s40261-014-0221-2.
14. Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407-13.
15. Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia. 2011;52:405-9.